Assessment of Pyroptosis-Related Indicators as Potential Biomarkers and Their Association with Severity in Patients with Liver Cirrhosis.
GSDMD
IL-18
IL-1ß
complication
liver cirrhosis
severity
Journal
Journal of inflammation research
ISSN: 1178-7031
Titre abrégé: J Inflamm Res
Pays: New Zealand
ID NLM: 101512684
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
05
2021
accepted:
08
07
2021
entrez:
21
7
2021
pubmed:
22
7
2021
medline:
22
7
2021
Statut:
epublish
Résumé
The diagnosis and management of liver cirrhosis remain challenging due to its diverse clinical manifestations and elusive severity evaluation. Pyroptosis, an identified inflammatory form of cell death, has recently been reported to participate in cirrhosis development. Nonetheless, the clinical significance of pyroptosis in liver cirrhosis remains largely unexplored. One hundred and fifty-one liver cirrhosis patients either alone or in combination with various complications and twenty-nine gender- and age-matched healthy controls (HCs) were enrolled in this study. Pyroptosis-related indicators gasdermin D (GSDMD), IL-1ß and IL-18 were measured by IHC in tissue section and by ELISA in serum, respectively, and correlations of their circulating levels with disease severity as well as their potential as biomarkers for monitoring cirrhosis progression were evaluated. Increased levels of the circulating pyroptosis-related indicators GSDMD, IL-1ß and IL-18 were observed in liver cirrhosis patients, especially those with an etiology of viral infection. In addition, all three indicators were positively correlated with disease severity parameters, including Child-Pugh classification, APRI scores and compensated status. Furthermore, receiver operating characteristic (ROC) analysis showed that circulating IL-1ß exerted potential discriminating power for SBP occurrence in liver cirrhosis, but GSDMD possessed differentiating power for SBP in liver cirrhosis with ascites, which yielded area under the ROC curve (AUC) of 0.81 and 0.80, respectively. Liver cirrhosis patients exhibited increased levels of circulating GSDMD, IL-1ß and IL-18, all of which were positively correlated with disease severity. More importantly, the identified circulating IL-1ß and GSDMD exhibited potentials as novel biomarkers for liver cirrhosis patients presenting with SBP.
Identifiants
pubmed: 34285542
doi: 10.2147/JIR.S319213
pii: 319213
pmc: PMC8286130
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3185-3196Informations de copyright
© 2021 Wang et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Lancet. 2008 Mar 8;371(9615):838-51
pubmed: 18328931
Biochim Biophys Acta Rev Cancer. 2019 Aug;1872(1):1-10
pubmed: 31059737
J Hepatol. 2017 May;66(5):1037-1046
pubmed: 28167322
Biochim Biophys Acta. 2013 Jul;1832(7):876-83
pubmed: 23149387
Int J Mol Sci. 2020 Jul 01;21(13):
pubmed: 32630319
Mediators Inflamm. 2015;2015:508681
pubmed: 25892853
Ther Clin Risk Manag. 2008 Oct;4(5):919-25
pubmed: 19209274
Lab Invest. 2012 May;92(5):713-23
pubmed: 22411067
Pharmacol Ther. 2020 May;209:107511
pubmed: 32097669
World J Gastroenterol. 2015 Nov 7;21(41):11567-83
pubmed: 26556987
J Hepatol. 2020 Nov;73(5):1072-1081
pubmed: 32344052
Inflamm Res. 2020 Jul;69(7):683-696
pubmed: 32347316
J Clin Invest. 2017 Jan 3;127(1):55-64
pubmed: 28045404
Cell Death Dis. 2019 Sep 9;10(9):650
pubmed: 31501419
Hepatology. 2014 Mar;59(3):898-910
pubmed: 23813842
Immunobiology. 2020 Mar;225(2):151884
pubmed: 31822435
J Interferon Cytokine Res. 2008 Nov;28(11):643-51
pubmed: 18844579
Hepatology. 2018 May;67(5):1737-1753
pubmed: 29108122
Biomed Res Int. 2020 Jul 6;2020:3743962
pubmed: 32724800
Part Fibre Toxicol. 2016 Sep 20;13(1):51
pubmed: 27650313
Ann Hepatol. 2008 Oct-Dec;7(4):350-7
pubmed: 19034235
J Pathol. 2008 Jan;214(2):199-210
pubmed: 18161745
Liver Int. 2013 Jan;33(1):31-9
pubmed: 23121656
J Hepatol. 2005;42 Suppl(1):S100-7
pubmed: 15777564
Curr Opin Gastroenterol. 2018 Jul;34(4):266-271
pubmed: 29846263
Nephrol Dial Transplant. 2014 Jan;29(1):41-8
pubmed: 24026244
J Hepatol. 2013 Sep;59(3):583-94
pubmed: 23567086
Nat Rev Microbiol. 2009 Feb;7(2):99-109
pubmed: 19148178
World J Gastroenterol. 2009 Aug 21;15(31):3845-50
pubmed: 19701963
Med Clin North Am. 2020 Jul;104(4):647-662
pubmed: 32505258
World J Gastroenterol. 2009 Nov 28;15(44):5505-10
pubmed: 19938187
Int Immunopharmacol. 2020 Jul;84:106489
pubmed: 32304992
PLoS Pathog. 2019 Feb 27;15(2):e1007593
pubmed: 30811485
APMIS. 2014 May;122(5):392-8
pubmed: 23992404
EMS World. 2015 Oct;44(10):32-7
pubmed: 26561682
J Cell Physiol. 2019 Jun;234(6):7885-7892
pubmed: 30537070